CN115554374B - Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN115554374B CN115554374B CN202211252480.1A CN202211252480A CN115554374B CN 115554374 B CN115554374 B CN 115554374B CN 202211252480 A CN202211252480 A CN 202211252480A CN 115554374 B CN115554374 B CN 115554374B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- helicobacter pylori
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of traditional Chinese medicines, and in particular discloses a traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following components: 6-8 parts of mugwort leaf, 6-9 parts of cistanche salsa, 8-12 parts of fructus amomi, 6-9 parts of common andrographis herb, 5-9 parts of fenugreek seed, 8-12 parts of wrinkled gianthyssop herb, 15-20 parts of virgate wormwood herb and 2-6 parts of honey-fried licorice root. The traditional Chinese medicine composition for treating helicobacter pylori gastritis provided by the invention takes mugwort leaves, cistanche deserticola and fructus amomi as monarch drugs, herba andrographis paniculatae and fenugreek are used as ministerial drugs for clearing heat and removing toxicity, wrinkled giant hyssop and capillary artemisia are used as adjuvant drugs, and prepared licorice root is used for harmonizing the drugs, so that the effects of warming yang and removing toxicity and clearing heat are achieved together. The traditional Chinese medicine composition is prepared into the navel moxibustion noodle bowl, so that all traditional Chinese medicine components are absorbed by human body acupoints, and the degree of improving the clinical symptoms of helicobacter pylori gastritis is further improved through the compatibility of all the components, so that the navel moxibustion noodle bowl has higher popularization and application values.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating helicobacter pylori gastritis, and a preparation method and application thereof.
Background
Helicobacter pylori related gastritis is a chronic gastritis which takes helicobacter pylori as main pathogenic bacteria, and the infection rate of helicobacter pylori in China is about 52.2 percent at present. Helicobacter pylori infection can cause inflammatory changes in the gastric mucosa, and its pathogenic mechanism is not completely studied. Current studies indicate that there is abnormal regulation of the gastric epithelial cell signaling pathway following helicobacter pylori infection, which can gradually destroy the gastric epithelial cell structure, and chronic inflammation can lead to morphological and pathological changes of the gastric mucosa, if no therapeutic measures are taken, further development into intestinal tract, atypical hyperplasia and even canceration is possible.
Helicobacter pylori gastritis is slow in onset, symptoms are not specifically expressed, atypical abdominal distending pain, anorexia, burning heart and acid regurgitation, dry mouth and bitter taste and the like are not caused, and a symptomatic treatment method is generally adopted clinically, but the improvement degree is limited. In addition, triple and quadruple sterilization therapies are mostly adopted at present, however, the therapies are easy to cause drug resistance of organisms, and cause imbalance of intestinal flora, poor patient compliance and large side effects. How to effectively improve the treatment effect of helicobacter pylori gastritis and reduce the side effect of the medicine is still a problem which needs to be solved in clinic.
Disclosure of Invention
Aiming at the technical problems of large side effect and limited improvement degree of the medicines for treating helicobacter pylori in the prior art, the invention provides a traditional Chinese medicine composition for treating helicobacter pylori gastritis and a preparation method and application thereof.
The embodiment of the invention adopts the following technical scheme for achieving the purposes:
a traditional Chinese medicine composition for treating helicobacter pylori gastritis comprises the following components in parts by weight: 6-8 parts of mugwort leaf, 6-9 parts of cistanche salsa, 8-12 parts of fructus amomi, 6-9 parts of common andrographis herb, 5-9 parts of fenugreek seed, 8-12 parts of wrinkled gianthyssop herb, 15-20 parts of virgate wormwood herb and 2-6 parts of honey-fried licorice root.
Compared with the prior art, the traditional Chinese medicine composition for treating the helicobacter pylori gastritis provided by the invention takes mugwort leaf, cistanche salsa and fructus amomi as monarch, herba andrographis paniculatae and fenugreek as ministerial, wrinkled giant hyssop and virgate wormwood herb as assistant, and prepared licorice root is used for harmonizing medicines, and the effects of warming yang and resolving turbidity and clearing heat and detoxicating are achieved by the whole formula, so that the improvement degree of clinical symptoms of the helicobacter pylori gastritis is effectively improved.
Preferably, the composition comprises the following components in parts by weight: 7-8 parts of mugwort leaf, 7-9 parts of cistanche, 9-11 parts of fructus amomi, 7-9 parts of common andrographis herb, 6-8 parts of fenugreek, 9-11 parts of wrinkled gianthyssop, 17-19 parts of virgate wormwood herb and 3-5 parts of honey-fried licorice root.
Preferably, the composition comprises the following components in parts by weight: 8 parts of mugwort leaf, 8 parts of cistanche, 10 parts of fructus amomi, 8 parts of common andrographis herb, 7 parts of fenugreek, 10 parts of wrinkled gianthyssop, 18 parts of virgate wormwood herb and 4 parts of honey-fried licorice root.
The pharmacological actions of the traditional Chinese medicine components in the invention are as follows:
mugwort leaf: pungent, bitter and warm in flavor, can warm the liver, spleen and kidney meridians, has the effects of warming meridians to stop bleeding, dispelling cold to regulate menstruation, can warm qi and blood by external application to the meridians, can treat various pains caused by yang deficiency and cold excess or pathogenic wind-cold-dampness, and the like, and modern pharmacological researches show that the mugwort leaf has inhibition effect on various bacteria and fungi.
Cistanche deserticola: sweet and salty in flavor, warm in nature, enter kidney and large intestine meridians, tonify kidney yang, benefit kidney essence, moisten intestines and relieve constipation. Can be used for treating kidney yang deficiency, essence and blood deficiency, constipation due to intestinal dryness, etc. Modern pharmacological research shows that cistanche deserticola can strengthen the phagocytic capacity of abdominal cavity, raise lymphocyte conversion rate and delayed hypersensitivity index.
Fructus Amomi: pungent taste, warm nature, good property, spleen, stomach and kidney meridians, dampness resolving, qi moving, middle warming and antidiarrheal effects, and can be used for treating spleen and stomach dampness and qi stagnation syndrome, spleen and stomach deficiency cold vomiting and diarrhea, etc., promoting gastrointestinal transport function, inhibiting gastric acid secretion and pepsin activity, and preventing and protecting gastric ulcer.
Andrographis paniculata: bitter taste, cold nature, lung, stomach, large intestine, liver, gallbladder and bladder meridians, heat and dampness clearing, fire purging and toxin expelling. Can be used for treating damp heat syndrome such as dysentery and jaundice, sore of mouth and tongue, and sore throat, and has antibacterial, antipyretic, antiinflammatory, immunity enhancing, liver protecting, gallbladder function promoting, and antitumor effects.
Fenugreek: bitter in flavor, warm in nature, enters kidney, liver and stomach meridians, tonifies kidney yang, and dispels cold-dampness. Can be used for treating kidney deficiency, soreness of waist, cold pain of lower abdomen, cold hernia, distention of abdomen and hypochondrium, cold diarrhea, etc.
Wrinkled giant hyssop: pungent and slightly warm nature, enters spleen, stomach and lung meridians, and has the actions of resolving dampness with aromatics, and relieving vomiting, and relieving summer-heat. It is indicated for obstruction of summer-heat and damp-heat, and epigastric and abdominal distension and fullness. Has the modern pharmacological actions of spasmolysis, corrosion prevention, antibiosis and the like.
Capillary artemisia: bitter and pungent in flavor and slightly cold in nature. It has effects in invigorating spleen, stomach, liver, and gallbladder meridian, clearing away heat and dampness, promoting bile flow, and eliminating jaundice. It can be used for treating summer-heat and dampness, damp-heat, incoordination between liver and stomach, etc., and has effects of resisting tumor, relieving fever, and protecting liver.
Honey-fried licorice root: sweet in taste, neutral in nature, enters stomach, heart, lung and spleen meridians, supplements middle-jiao and qi, eliminates phlegm and relieves cough, relieves spasm and pain, and harmonizes drug properties. Has effects of treating spleen and stomach weakness and harmonizing various medicines. Can be used for treating spleen and stomach weakness, and has modern pharmacological effects of resisting helicobacter pylori and ulcer.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating helicobacter pylori gastritis, which at least comprises the following steps:
weighing the components according to the designed proportion, crushing the weighed mugwort leaf, cistanche salsa, fructus amomi, common andrographis herb, fenugreek seed, wrinkled gianthyssop herb, virgate wormwood herb and honey-fried licorice root into powder, and uniformly mixing to obtain the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
The invention also provides application of the traditional Chinese medicine composition for treating helicobacter pylori gastritis in preparing a helicobacter pylori treatment medicine.
The invention also provides a traditional Chinese medicine preparation for treating helicobacter pylori gastritis, which comprises any one of the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
Preferably, the Chinese medicinal preparation is an external medicinal preparation.
The traditional Chinese medicine composition for treating helicobacter pylori gastritis is prepared into a traditional Chinese medicine preparation, is convenient to carry and use and is easy to operate.
Preferably, the use method of the traditional Chinese medicine preparation comprises the following steps: the traditional Chinese medicine preparation is prepared into an umbilical moxibustion surface bowl, and moxibustion is carried out on the navel part.
Preferably, the use method of the traditional Chinese medicine preparation comprises the following steps: it is administered 1 time daily for 4 weeks.
The traditional Chinese medicine preparation is prepared into the navel moxibustion noodle bowl, so that all traditional Chinese medicine components are absorbed by human body acupoints, and the degree of improving the clinical symptoms of helicobacter pylori gastritis is further improved through the compatibility of all the components.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
The embodiment of the invention provides a traditional Chinese medicine composition for treating helicobacter pylori gastritis, which comprises the following components in parts by weight: 8 parts of mugwort leaf, 8 parts of cistanche, 10 parts of fructus amomi, 8 parts of common andrographis herb, 7 parts of fenugreek, 10 parts of wrinkled gianthyssop, 18 parts of virgate wormwood herb and 4 parts of honey-fried licorice root.
The preparation method of the traditional Chinese medicine composition for treating helicobacter pylori gastritis at least comprises the following steps:
weighing the components according to the designed proportion, crushing the weighed mugwort leaf, cistanche salsa, fructus amomi, common andrographis herb, fenugreek seed, wrinkled gianthyssop herb, virgate wormwood herb and honey-fried licorice root into powder, and uniformly mixing to obtain the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
Example 2
The embodiment of the invention provides a traditional Chinese medicine composition for treating helicobacter pylori gastritis, which comprises the following components in parts by weight: 6 parts of mugwort leaf, 9 parts of cistanche, 8 parts of fructus amomi, 9 parts of common andrographis herb, 5 parts of fenugreek, 12 parts of wrinkled gianthyssop herb, 15 parts of virgate wormwood herb and 2 parts of honey-fried licorice root.
The preparation method of the traditional Chinese medicine composition for treating helicobacter pylori gastritis at least comprises the following steps:
weighing the components according to the designed proportion, crushing the weighed mugwort leaf, cistanche salsa, fructus amomi, common andrographis herb, fenugreek seed, wrinkled gianthyssop herb, virgate wormwood herb and honey-fried licorice root into powder, and uniformly mixing to obtain the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
Example 3
The embodiment of the invention provides a traditional Chinese medicine composition for treating helicobacter pylori gastritis, which comprises the following components in parts by weight: 7 parts of mugwort leaf, 6 parts of cistanche salsa, 12 parts of fructus amomi, 6 parts of common andrographis herb, 9 parts of fenugreek, 8 parts of wrinkled gianthyssop herb, 20 parts of virgate wormwood herb and 6 parts of honey-fried licorice root.
The preparation method of the traditional Chinese medicine composition for treating helicobacter pylori gastritis at least comprises the following steps:
weighing the components according to the designed proportion, crushing the weighed mugwort leaf, cistanche salsa, fructus amomi, common andrographis herb, fenugreek seed, wrinkled gianthyssop herb, virgate wormwood herb and honey-fried licorice root into powder, and uniformly mixing to obtain the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
Comparative example 1
The comparative example provides a traditional Chinese medicine composition for treating helicobacter pylori gastritis, the composition of raw materials and the dosage of the raw materials are identical to those of the example 1, except that common andrographis herb is replaced by dandelion with equal quantity, fructus amomi is replaced by cardamom with equal quantity, and the traditional Chinese medicine composition specifically comprises:
8 parts of mugwort leaf, 8 parts of cistanche salsa, 10 parts of cardamon, 8 parts of dandelion, 7 parts of fenugreek, 10 parts of wrinkled gianthyssop, 18 parts of virgate wormwood herb and 4 parts of honey-fried licorice root.
A Chinese medicinal composition for treating helicobacter pylori gastritis was prepared in exactly the same manner as in example 1.
In order to better illustrate the characteristics of the traditional Chinese medicine composition for treating helicobacter pylori gastritis provided by the embodiment of the invention, the traditional Chinese medicine composition for treating helicobacter pylori gastritis prepared in the embodiment 1 is subjected to effect test.
The invention is described in further detail below in connection with clinical trials and typical cases.
1. Clinical trial
1. Clinical data:
1.1 general data
120 patients with helicobacter pylori gastritis in outpatient service and hospitalization are selected and divided into 3 groups by adopting an electronic random number method, namely 40 groups of treatment groups of the example, treatment groups of the comparative example and control groups. The treatment group of examples had 24 men and 16 women, on average (40.75.+ -. 11.71 years old). Comparative example treatment group 23 men and 17 women, average (41.37.+ -. 10.64 years old). Control men 22 and 18 women, average (39.83.+ -. 11.55 years). The general data were comparable with no statistical difference (P > 0.05).
1.2 diagnostic criteria
The Western medicine diagnosis standards refer to Chinese chronic gastritis consensus opinion (2017, shanghai), chinese and Western medicine combined diagnosis and treatment consensus opinion (2017), and Chinese and Western medicine combined diagnosis and treatment consensus opinion (2017).
The method comprises the following steps: (1) clinical symptoms: stomach ache, fullness, belch, borygmus, dry mouth, bitter taste, etc.; (2) And through laboratory 14 C Positive in the expiration test.
1.3 inclusion criteria
(1) Gastroscopy for diagnosing chronic gastritis and having clinical symptoms; (2) age 20-70 years; (3) helicobacter pylori positive patients; (4) and signing an informed consent form.
1.4 exclusion criteria
(1) Patients with extreme fatigue or poor mental state due to other causes; (2) certain skin or infectious disease onset or other site of administration contraindications to patients; (3) women in gestation and lactation; (4) allergic constitution or allergic to various drugs.
2. The treatment method comprises the following steps:
the example treatment group, the comparative treatment group and the control group were each given a four-way bactericidal: esomeprazole magnesium enteric-coated tablets (Abies lican pharmaceutical Co., ltd., national drug standard number H20046379, specification: 20mg×7 tablets) 20mg each time, 2 times/day; ornidazole dispersible tablet (Hunan Jiudian pharmaceutical Co., ltd., national drug substance standard character size H20040460, specification: 0.25 g. Times.24 tablet) 0.5g each time, 2 times/day; amoxicillin dispersible tablet (Shanxi Tongda pharmaceutical Co., ltd., national drug standard character size H20000492, specification: 500 mg. Times.24 tablet) 1.0g each time, 2 times/day; bismuth potassium citrate granules (Lizhu group Lizhu pharmaceutical factory, national drug standard number H10900086, specification: 1.0g×56 bag) for 2 weeks.
2.1 example treatment group: by applying the external treatment method of the invention to the moxibustion of the navel, 8g of mugwort leaf, 8g of cistanche salsa, 10g of fructus amomi, 8g of common andrographis herb, 7g of fenugreek, 10g of wrinkled gianthyssop herb, 18g of virgate wormwood herb and 4g of honey-fried licorice root, the 8 traditional Chinese medicines are prepared into uniform medicinal powder for standby, the preparation is externally used by bowl navel moxibustion for 1 time a day, and the treatment period is 4 weeks.
2.2 comparative treatment group: the external treatment method for the navel moxibustion of the invention is characterized in that 8g of mugwort leaf, 8g of cistanche salsa, 10g of wrinkled giant hyssop, 8g of black nightshade, 7g of fenugreek, 10g of wrinkled giant hyssop, 18g of virgate wormwood herb and 4g of honey-fried licorice root are prepared into uniform medicinal powder for standby, 1 time a day, the external treatment period of the navel moxibustion of the navel bowl is 4 weeks.
2.3 control group: the traditional Chinese medicine of the invention is administered with placebo (200 g of rice is stir-fried to brown and the dosage of the original medicine is 1/20), the traditional Chinese medicine is externally used by the navel moxibustion of the bowl type for 1 time a day, and the treatment period is 4 weeks.
3, observing indexes: clinical symptoms (gastralgia, distention, belch, borborygmus, dry mouth, bitter taste), tongue coating, tongue quality, electrogastrogram, and quality of life.
3.1 clinical symptoms: stomach ache, distention, belch, borygmus, dry mouth and bitter taste. The accumulation of symptom scores is carried out according to the severity of clinical symptoms of patients, and the symptoms are more serious when the score is higher, namely, the score is 3, the score is 2, the score is 1 and the score is 0, and vice versa. The treatment period was recorded weekly.
3.2 tongue coating and tongue mass change: the change of tongue coating caused by bismuth agent is eliminated, and the changes of red and dark tongue, fat and big tooth trace, thick and thin coating, yellow and white coating and the like are observed.
3.3 Electrogastroenterology examination: the electrotometer-gastrointegrogram octaguide (EGEG-8D) is adopted, the stomach body, the lesser curvature, the greater curvature of the stomach, the antrum, the ascending colon, the transverse colon, the descending colon and the rectus myoelectricity are monitored simultaneously in each operation process, and the test result is stored in a computer for further study.
3.4 quality of life table: the clinical outcome (PRO) score scale based on patient reports contains 4 dimensions (dyspepsia, general condition, psychology, society) and 35 entries, has better credibility, effectiveness and responsiveness, 9 entries in the dyspepsia field, 4 entries in the general condition field, 4 entries in the psychology field, and 3 entries in the social field. The total score of the quality of life in each field can be 100 points, and the lower the score, the higher the quality of life is, the change of the scores before and after two groups of treatments is observed.
4. Efficacy assessment criteria:
referring to the clinical guidelines of new traditional Chinese medicine, clinical cure: symptoms and signs disappear or disappear basically, and the integral of symptoms is reduced by more than or equal to 95 percent; the effect is shown: the symptoms and signs are obviously improved, and the integral of the symptoms is reduced by more than or equal to 70 percent; the method is effective: the symptoms and signs are all improved, and the integral reduction of the symptoms is more than or equal to 30 percent; invalidation: the clinical symptoms and signs are not relieved or aggravated, and the integral of the symptoms is reduced by less than 30 percent compared with the prior symptoms. The calculation formula of the percentage reduction of the symptom integral adopts the nimodipine method.
5. Before and after treatment, adverse reactions such as blood, urine, stool convention, electrocardiogram, liver and kidney functions and gastrointestinal tract observation of patients are detected.
6. Statistical method
The data were statistically analyzed using SPSS 25.0 software. The metering data are in accordance with normal distribution and expressed by mean ± standard deviation (x ± s); paired t-test is adopted before and after treatment in the group, comparison is carried out between groups, if normal distribution is met, two independent sample t-test is selected, and if the two independent sample t-test does not accord with the normal distribution, rank sum test is selected; rank sum test is used for the rank efficacy assessment data. The difference of P < 0.05 is statistically significant.
7. Treatment results:
7.1 total integral contrast of the chief complaints after treatment of two groups of patients: stomach ache, distention, belch, borygmus, dry mouth and bitter taste.
Table 1 total integral of the principal symptoms after treatment of two groups of patients
Note that: the total integral of the symptoms before treatment of the three groups has no statistical significance (P is more than 0.05), the three groups have statistical difference compared with the pre-treatment comparison, * p is less than 0.05; the treatment group of the example was compared with the treatment group of the comparative example and the treatment group of the control, △ P＜0.05。
as can be seen from the data in Table 1, three groups of pre-treatment symptoms total productNo statistical significance (P > 0.05) was found for the total score of the principal symptoms was reduced between the three groups compared to that before treatment, P < 0.05; the example treated group was statistically different from the comparative treated group and the control treated group, △ p < 0.05, and symptom relief of the treatment group of the example is superior to that of the treatment group of the comparative example and the control group.
7.2 comparison of tongue coating and tongue changes after treatment for two groups of patients:
table 2 changes in tongue coating and tongue quality (examples (%))
Note that: p is less than 0.05 before and after the treatment among the three groups; the example treatment group-to-group variation was superior to the comparative treatment group control group and control group, * p is less than 0.05. The control example treatment group had a better group-to-group variation than the control group, △ P＜0.05。
as can be seen from the data in table 2, the tongue coating and tongue quality are improved before and after the treatment of the three groups, the difference has statistical significance (P < 0.05), the change between the groups of the example treatment group is superior to that of the control group and the control group of the comparative example treatment group, and the number of tongue coating and tongue quality improvement of the example treatment group is more than that of the control group of the comparative example treatment group, (. P < 0.05); the tongue coating and tongue improvement number of the comparative treatment group are more than those of the control group △ P＜0.05)。
7.3 comparison of average amplitude of Electrogastroenterogram of Main part after treatment of two groups of patients
Table 3 average amplitude integral of the main part electrogram after treatment of two groups of patients
Note that: compared with the physiological state of the lead, P is less than 0.05, compared with the treatment of the comparative example treatment group and the control group, * P＜0.05。
from the above table data, it can be seen that, compared with the electrogastrogram under normal physiological conditions: the average amplitude of the treatment group of the example, the treatment group of the comparative example and the control group is reduced (P is less than 0.05); the mean amplitude was further reduced (< 0.05) for the same lead treatment group compared to the comparative and control groups, and the differences were statistically significant. The example treated group decreased more than the comparative example treated group and the control group.
7.4 PRO rating scale score comparison of two groups of patients before and after treatment:
table 4 comparison of PRO rating scale scores before and after treatment for two groups of patients
Note that P < 0.05 for the three groups compared to the same group prior to treatment; example treatment group treatment was followed by comparison with the comparative example treatment group treatment and the control group treatment, * P＜0.05。
as can be seen from the table above, the PRO rating scale scores of the three groups are reduced compared with those of the three groups before treatment, and the P is less than 0.05; the score of the treatment group of the example is reduced compared with that of the treatment group of the comparative example and the control group, namely the quality of life of the treatment group of the example is better than that of the other two groups, and the treatment group of the example has statistical difference, and the P is less than 0.05.
In conclusion, the traditional Chinese medicine composition for treating helicobacter pylori gastritis provided by the invention has the characteristics of simple formula, convenience in use, reliable curative effect and no toxic or side effect, can improve the degree of improvement of clinical symptoms of helicobacter pylori gastritis, accelerates recovery of gastrointestinal functions, and is suitable for long-term use.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (9)
1. The traditional Chinese medicine composition for treating helicobacter pylori gastritis is characterized by being prepared from the following components in parts by weight: 6-8 parts of mugwort leaf, 6-9 parts of cistanche salsa, 8-12 parts of fructus amomi, 6-9 parts of common andrographis herb, 5-9 parts of fenugreek seed, 8-12 parts of wrinkled gianthyssop herb, 15-20 parts of virgate wormwood herb and 2-6 parts of honey-fried licorice root.
2. The traditional Chinese medicine composition for treating helicobacter pylori gastritis according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following components in parts by weight: 7-8 parts of mugwort leaf, 7-9 parts of cistanche, 9-11 parts of fructus amomi, 7-9 parts of common andrographis herb, 6-8 parts of fenugreek, 9-11 parts of wrinkled gianthyssop, 17-19 parts of virgate wormwood herb and 3-5 parts of honey-fried licorice root.
3. The traditional Chinese medicine composition for treating helicobacter pylori gastritis according to claim 2, wherein the traditional Chinese medicine composition is prepared from the following components in parts by weight: 8 parts of mugwort leaf, 8 parts of cistanche, 10 parts of fructus amomi, 8 parts of common andrographis herb, 7 parts of fenugreek, 10 parts of wrinkled gianthyssop, 18 parts of virgate wormwood herb and 4 parts of honey-fried licorice root.
4. A method for preparing a traditional Chinese medicine composition for treating helicobacter pylori gastritis as defined in any one of claims 1 to 3, characterized by comprising at least the following steps:
weighing the components according to the proportion, crushing the weighed mugwort leaf, cistanche salsa, fructus amomi, common andrographis herb, fenugreek seed, wrinkled gianthyssop herb, virgate wormwood herb and honey-fried licorice root into powder, and uniformly mixing to obtain the traditional Chinese medicine composition for treating helicobacter pylori gastritis.
5. Use of a Chinese medicinal composition for treating helicobacter pylori gastritis according to any one of claims 1-3 in the preparation of a medicament for treating helicobacter pylori.
6. A Chinese medicinal preparation for treating helicobacter pylori gastritis, which is characterized by comprising the Chinese medicinal composition for treating helicobacter pylori gastritis according to any one of claims 1 to 3.
7. The Chinese medicinal preparation for treating helicobacter pylori gastritis according to claim 6, wherein: the traditional Chinese medicine preparation is an external medicine preparation.
8. The Chinese medicinal preparation for treating helicobacter pylori gastritis according to claim 6 or 7, wherein: the use method of the traditional Chinese medicine preparation comprises the following steps: the traditional Chinese medicine preparation is prepared into an umbilical moxibustion surface bowl, and moxibustion is carried out on the navel part.
9. The Chinese medicinal preparation for treating helicobacter pylori gastritis according to claim 8, wherein: the use method of the traditional Chinese medicine preparation comprises the following steps: it is administered 1 time daily for 4 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211252480.1A CN115554374B (en) | 2022-10-13 | 2022-10-13 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211252480.1A CN115554374B (en) | 2022-10-13 | 2022-10-13 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115554374A CN115554374A (en) | 2023-01-03 |
| CN115554374B true CN115554374B (en) | 2023-07-07 |
Family
ID=84744799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211252480.1A Active CN115554374B (en) | 2022-10-13 | 2022-10-13 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115554374B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940791A (en) * | 2015-07-12 | 2015-09-30 | 济南超舜中药科技有限公司 | Traditional Chinese medicine pills for treating chronic gastritis and preparation method thereof |
| CN105535784A (en) * | 2016-01-07 | 2016-05-04 | 大连大学 | Traditional Chinese medicine composition for treating stomach illness and application thereof |
| CN105770673A (en) * | 2016-04-12 | 2016-07-20 | 广州三得医疗科技有限公司 | Application of Chinese herba preparation containing folium artemisiae argyi in preparing drug for treating chronic gastritis |
| CN111991535A (en) * | 2020-09-28 | 2020-11-27 | 河北省中医院 | Traditional Chinese medicine extract with function of treating Hp-related gastritis and preparation method and application thereof |
-
2022
- 2022-10-13 CN CN202211252480.1A patent/CN115554374B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940791A (en) * | 2015-07-12 | 2015-09-30 | 济南超舜中药科技有限公司 | Traditional Chinese medicine pills for treating chronic gastritis and preparation method thereof |
| CN105535784A (en) * | 2016-01-07 | 2016-05-04 | 大连大学 | Traditional Chinese medicine composition for treating stomach illness and application thereof |
| CN105770673A (en) * | 2016-04-12 | 2016-07-20 | 广州三得医疗科技有限公司 | Application of Chinese herba preparation containing folium artemisiae argyi in preparing drug for treating chronic gastritis |
| CN111991535A (en) * | 2020-09-28 | 2020-11-27 | 河北省中医院 | Traditional Chinese medicine extract with function of treating Hp-related gastritis and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 中医药治疗幽门螺杆菌感染研究进展;麦恩华;钟毅;;广西中医药大学学报;第23卷(第01期);64-67 * |
| 中医辨证治疗脾胃湿热证慢性浅表性胃炎;袁永贵;;深圳中西医结合杂志;第28卷(第19期);62-63 * |
| 中西医结合治疗慢性胃炎32例临床观察;李丹青;吴艳华;;新中医;第44卷(第07期);40-42 * |
| 解毒化浊法辨治幽门螺杆菌相关性溃疡78例;李海滨;;山东中医药大学学报;第33卷(第04期);308-309 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115554374A (en) | 2023-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998843A (en) | Medicinal composition for treating cholecystitis | |
| CN102284049B (en) | A kind ofly alleviate compound Chinese medicinal preparation of chemicotherapy toxicity and uses thereof | |
| CN111991535B (en) | Traditional Chinese medicine extract with function of treating helicobacter pylori-associated gastritis and preparation method and application thereof | |
| CN108853258A (en) | A kind of Chinese medicine composition that treating functional consitipation and its application | |
| CN115554374B (en) | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN113768978B (en) | Yi medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN111228367B (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
| CN105833115A (en) | Traditional Chinese medicine for treating precancerous lesions of gastric cancer | |
| CN101693084A (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
| CN113769002B (en) | Traditional Chinese medicine decoction for treating gastritis verrucosa | |
| CN103520575A (en) | Chinese medicinal preparation for treating spleen-stomach damp-heat type chronic gastritis and preparation method thereof | |
| CN117414351B (en) | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof | |
| CN113633748B (en) | Medicine for treating spontaneous bacterial peritonitis damp-heat stasis syndrome of liver cirrhosis and preparation method thereof | |
| Xiao | Clinical Effect of Integrated Traditional Chinese and Western Medicine Treatment on Early Postoperative Inflammatory Small Bowel Obstruction | |
| CN106491974B (en) | Traditional Chinese medicine composition and traditional Chinese medicine decoction for treating enteroparalysis | |
| CN116966249A (en) | Traditional Chinese medicine composition for treating ulcerative colitis | |
| CN117883536A (en) | Traditional Chinese medicine composition for treating intestinal inflammation and cancer transformation diseases and application thereof | |
| CN117959405A (en) | Traditional Chinese medicine composition for diarrhea type irritable bowel syndrome and preparation method and application thereof | |
| Xu | TCM and Western Medicine: Diagnosis and Treatment of Novel Coronavirus Pneumonia, A Case Study | |
| CN104825937A (en) | Chinese herbal preparation for treating chronic colitis and preparation method thereof | |
| CN117138007A (en) | Traditional Chinese medicine composition for treating helicobacter pylori and preparation method thereof | |
| CN117122661A (en) | Traditional Chinese medicine composition and preparation for treating chronic cholecystitis liver Yu Dan heat syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |